Oct 7, 2026 · 27 min · 14 segments
Crain’s assistant managing editor Ann Weiler joins host Jeanne Sparrow to discuss the 40 Under 40 Class of 2026. Plus…
Jeanne SparrowHostAnne WeilerGuest
Crain's John Asplund reports that unlike traditional vaccines, this experimental treatment, known as Intysmerin Autogene, is custom-built for each patient.
Scientists analyze genetic data from a patient's tumor, then design a targeted vaccine that trains the immune system to recognize and destroy those specific cancer cells.
If cleared by regulators, it would become the first drug in history made using personalized genetic sequencing.
Under the expanded deal, the company will manage the collection of patient tissue and blood samples and perform the genetic sequencing required to build each individual dose.
Tempus is also in the process of acquiring Personalis, the sequencing firm that powered the vaccine's clinical trials in a one point seven billion dollar deal.
Financial details weren't disclosed, but Wall Street analysts at Guggenheim say the deal is a huge win for Tempus.
Because genetic sequencing is baked directly into the manufacturing process rather than just patient screening, Tempus becomes an essential link in the supply chain, making them nearly impossible for drug makers to replace.
The news follows encouraging phase three clinical trial results testing the vaccine alongside Merck's cancer drug Keytruda in melanoma patients.
Tempus founder and CEO Eric Lefkofsky called individualized therapies the future of precision medicine, stating the partnership builds the real-world infrastructure needed to get personalized vaccines directly to patients.
Crain's John Asplund reports that unlike traditional vaccines, this experimental treatment, known as Intysmerin Autogene, is custom-built for each patient.
Scientists analyze genetic data from a patient's tumor, then design a targeted vaccine that trains the immune system to recognize and destroy those specific cancer cells.
If cleared by regulators, it would become the first drug in history made using personalized genetic sequencing.
Under the expanded deal, the company will manage the collection of patient tissue and blood samples and perform the genetic sequencing required to build each individual dose.
Tempus is also in the process of acquiring Personalis, the sequencing firm that powered the vaccine's clinical trials in a one point seven billion dollar deal.
Financial details weren't disclosed, but Wall Street analysts at Guggenheim say the deal is a huge win for Tempus.
Because genetic sequencing is baked directly into the manufacturing process rather than just patient screening, Tempus becomes an essential link in the supply chain, making them nearly impossible for drug makers to replace.
The news follows encouraging phase three clinical trial results testing the vaccine alongside Merck's cancer drug Keytruda in melanoma patients.
Tempus founder and CEO Eric Lefkofsky called individualized therapies the future of precision medicine, stating the partnership builds the real-world infrastructure needed to get personalized vaccines directly to patients.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.